High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer.
T Vuong, S Devic, E Podgorsak
https://pubmed.ncbi.nlm.nih.gov/17714925/Actively Recruiting
Led by Dr. Te Vuong · Updated on 2026-10-28
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
Researchers are evaluating a targeted internal radiation treatment called HDR brachytherapy followed by two doses of the immunotherapy drug Nivolumab before surgery to remove rectal cancer. This Phase II study focuses on patients with locally advanced, mismatch repair proficient rectal cancer to assess safety, feasibility, and potential effectiveness. Participants receive HDR brachytherapy with a total dose of 26 Gy divided into 4 sessions over four days. Starting 7 to 14 days after brachytherapy, they receive up to two intravenous doses of Nivolumab every two weeks. Surgical removal of the tumor through total mesorectal excision is planned 6 to 8 weeks after completing brachytherapy, up to a maximum of 12 weeks. During the study, participants undergo monitoring including assessments of tumor response at surgery approximately 12 weeks after enrollment. Researchers track adverse events from the first treatment through 90 days after the last Nivolumab dose. Feasibility of the treatment sequence is also evaluated. Overall participation lasts about 12 weeks from enrollment to surgery.
CONDITIONS
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Dr. Te Vuong
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks
Participants receive HDR brachytherapy over 4 days, followed by up to two doses of Nivolumab given every 2 weeks starting 7 to 14 days after brachytherapy. Surgery to remove the tumor is planned 6 to 8 weeks after brachytherapy completion.
Multiple visits for radiation, immunotherapy, and surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
T Vuong, S Devic, E Podgorsak
https://pubmed.ncbi.nlm.nih.gov/17714925/Z Y Lin, P Zhang, P Chi...
https://pubmed.ncbi.nlm.nih.gov/38964714/Dr. Te Vuong
Lead Sponsor